Affimed Announces Third Quarter 2018 Financial Results and Corporate Update Conference Call on November 7, 2018

Press Release - October 31, 2018


Heidelberg, Germany, October 31, 2018 – Affimed N.V. (Nasdaq: AFMD), a clinical stage biopharmaceutical company focused on discovering and developing highly targeted cancer immunotherapies, today announced that it will host a conference call on Wednesday, November 7, 2018 at 8:30 a.m. ET to discuss its third quarter financial results and recent corporate developments.

The conference call will be available via phone and webcast. To access the call, please dial (323) 794-2588 for U.S. callers, or +44 (0)330 336 9125 for international callers, and reference conference ID 6650897 approximately 15 minutes prior to the call. An audio webcast of the conference call can be accessed in the “Events” section on the “Investors & Media” page of the Affimed website at A replay of the webcast will be available on Affimed’s website shortly after the conclusion of the call and will be archived on the Affimed website for 30 days following the call.

About Affimed N.V.

Affimed (Nasdaq: AFMD) engineers targeted immunotherapies, seeking to cure patients by harnessing the power of innate and adaptive immunity (NK and T cells). We are developing single and combination therapies to treat cancers and other life-threatening diseases. For more information, please visit

Affimed Media Contact:

Anca Alexandru, Head of Communications, EU IR E-Mail:

Affimed Investor Contact:

Gregory Gin, Head of Investor Relations E-Mail: